0.04Open0.05Pre Close25 Volume247 Open Interest1.50Strike Price100.00Turnover181.66%IV69.60%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.2049Delta0.6644Gamma22.70Leverage Ratio-0.0025Theta0.0001Rho4.65Eff Leverage0.0007Vega
Karyopharm Therapeutics Stock Discussion
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...
No comment yet